A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2016
At a glance
- Drugs PF 6473871 (Primary)
- Indications Scars
- Focus Therapeutic Use
- Sponsors Pfizer
- 15 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 14 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.